Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04374305 · ClinicalTrials.gov registry record · Phase 2
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)
A Phase 2 study of Meningioma and Ependymoma, sponsored by Scott R. Plotkin, MD, PhD.
- Active
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 6
- Study locations
NCT04374305 is a Phase 2 study of Meningioma and Ependymoma that is active but no longer recruiting, run by Scott R. Plotkin, MD, PhD. The registered enrollment target is 100 participants, roughly in line with the 95-participant average among 21 other Meningioma trials with a reported enrollment target. The trial reports 6 study locations across 6 states.
The verdict
NCT04374305, a Phase 2 study of Meningioma and Ependymoma, is active but no longer recruiting, sponsored by Scott R. Plotkin, MD, PhD.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 6
- Study locations
Study Summary
This is a multi-arm phase II platform-basket screening study designed to test multiple experimental therapies simultaneously in patients with NF2-related schwannomatosis (NF2-SWN, formerly known as neurofibromatosis type 2) with associated progressive tumors of vestibular schwannomas (VS), non-vestibular schwannomas (non-VS), meningiomas, and ependymomas. This Master Study is being conducted as a "basket" study that may allow people with multiple tumor types associated with NF2-SWN to receive new drugs throughout this study. Embedded within the Master Study are individual drug substudies. * Investigational Drug Sub-study A: Brigatinib * Investigational Drug Sub-study B: Neratinib
Conditions Studied
Interventions
- DRUG Neratinib
- DRUG Brigatinib
Study Locations (6)
California
- UCLA Medical Center - Los Angeles
Florida
- University of Miami - Miami
Indiana
- Indiana University School of Medicine - Indianapolis
Maryland
- Johns Hopkins Hospital - Baltimore
Massachusetts
- Massachusetts General Hospital - Boston
New York
- New York University Langone Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2020-06-20 |
| Est. Completion | 2030-12-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04374305
The ClinicalTrials.gov registry entry for NCT04374305 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 95-participant average among 21 other Meningioma trials with a reported enrollment target. The listed sponsor is Scott R. Plotkin, MD, PhD, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Meningioma appearing as the primary indexed condition, and to 2 interventions - of which Neratinib is the first listed.
NCT04374305 reports 6 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Indiana.
Frequently Asked Questions
What is clinical trial NCT04374305 about?
NCT04374305 is a clinical study titled "Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)". This is a multi-arm phase II platform-basket screening study designed to test multiple experimental therapies simultaneously in patients with NF2-related schwannomatosis (NF2-SWN, formerly known as neurofibromatosis type 2) with associated progressive tumors of vestibular schwannomas (VS), non-vesti...
What is the current status of trial NCT04374305?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2020-06-20. Estimated completion is 2030-12-01.
What conditions does trial NCT04374305 study?
This clinical trial studies the following conditions: Meningioma, Ependymoma, Vestibular Schwannoma, Neurofibromatosis Type 2, Non-vestibular Schwannoma.
What interventions are being tested in trial NCT04374305?
The interventions under investigation include: Neratinib (DRUG), Brigatinib (DRUG).
Who is sponsoring clinical trial NCT04374305?
This trial is sponsored by Scott R. Plotkin, MD, PhD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04374305 being conducted?
This trial has 6 study locations across California, Florida, Indiana, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Meningioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Abemaciclib in Newly Diagnosed Meningioma Patients
RECRUITING · Phase 2
-
Cabozantinib for Patients With Recurrent or Progressive Meningioma
RECRUITING · Phase 2
-
Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial
RECRUITING · Phase 2
-
Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma
ACTIVE NOT RECRUITING · Phase 2
-
Monthly SOM230C for Recurrent or Progressive Meningioma
COMPLETED · Phase 2
-
AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.